|COUNTRY OF ORIGIN||India|
|INDICATION||Treatment of Chronic hepatitis C virus (HCV) infection|
|PACKAGING||28 tablets in 1 strip|
|MANUFACTURER||Natco Pharma Ltd|
|COMPOSITION||Ledipasvir (90mg) + Sofosbuvir (400mg)|
Our valuable clients can avail from us a quality approved?Hepcinat LP?that is combination of Sofosbuvir 400 mg and Ledipasvir 90 mg. The provided tablets are available for the clients at budget friendly prices.
- Medicine Name: Hepcinat -LP
- Active Ingredients: Sofosbuvir 400mg and Ledipasvir 90mg
- Dosage Form: Tablets in bottle.
- Retail Pack: Pack of 28 Tablets
- Company Name: NATCO PHARMA LTD.
Hepcinat-LP Tablet is a combination of two antiviral medicines. This prescription medicine is used in the treatment of chronic hepatitis C virus (HCV) infection. It fights against the viruses to resolve the infection.
Hepcinat-LP Tablet should be taken in the prescribed dose and duration. It can be taken with or without food, but take it at the same time daily. It is advised not to consume more than the recommended dose. It is important to inform your doctor if you have any health conditions such as liver or kidney disease. It is harmful to consume alcohol along with this medicine, so it is advised to limit or avoid alcohol. The course of the medicine should be completed for better results.
The common side effects of this medicine are tiredness and headache. You should drink plenty of fluid and eat a healthy diet to prevent or overcome the side effects. Before taking the medicine, inform your doctor if you are taking any other medicines or supplements.
USES OF HEPCINAT-LP TABLET
- Treatment of?Chronic hepatitis C virus (HCV) infection
SIDE EFFECTS OF HEPCINAT-LP TABLET
Common side effects of Hepcinat-LP
HOW TO USE HEPCINAT-LP TABLET
HOW HEPCINAT-LP TABLET WORKS
Hepcinat-LP Tablet, when taken together with other medicines for the treatment of hepatitis c infection, may produce dizziness, blurred vision and this may affect your ability to drive.
Limited information is available on use of Hepcinat-LP Tablet in these patients. No dose adjustment is recommended in patients with mild to moderate kidney disease.